| Labcorp

April 1, 2023

Now Offering Droplet Digital PCR (ddPCR) and NanoString nCounter

Labcorp now offers ddPCR services to allow nucleic acid quantification with ultrasensitivity and high precision using Bio-Rad's QX200 System, as well as NanoString nCounter services providing off-the-shelf and custom panels to inform how a drug modulates gene expression and signaling pathways.

April 3, 2023

Second generation mRNA vaccines: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant

WVC 2023 -- Messenger RNA (mRNA) vaccines have attracted increasing attention as a promising and adaptable alternative to conventional vaccine modalities. mRNA vaccine efficacy relies on the vaccine's ability to the reach the cytoplasm of the target cells in high quantities where it can be translated into the antigen of interest.

<span>Environmental Risk Assessment for Pharmaceutical Drugs: Understanding the Evaluation and Implications of Findings to the Regulatory Review of Human Medicines in the Environment</span>

April 6, 2023

Environmental Risk Assessment for Pharmaceutical Drugs: Understanding the Evaluation and Implications of Findings to the Regulatory Review of Human Medicines in the Environment

Pharmaceutical drugs are intended for the treatment of human disease, therefore the risk of their environmental exposure in clinical use needs to be evaluated. Environmental risk assessment (ERA) is part of the requirements when applying for marketing approval in many geographic regions throughout the world.

April 7, 2023

20 critical questions: Helping you optimize reference standards for your biopharmaceutical across its development life cycle

This white paper explores challenges in understanding, identifying and managing reference standards for biopharmaceuticals. Their characterization is more nuanced than is the case for standards for small molecules.

April 7, 2023

mRNA-lipid nanoparticles: Quality control releasing testing and characterization

The regulatory authorizations and approvals of the Pfizer and Moderna COVID-19 vaccines proved to be a trailblazer for the mRNA-LNP modality and opened the pathway for regulatory approvals of a whole raft of similar mRNA-based products.

April 13, 2023

United partnerships deliver for the client in a complex NASH study

An internal operations pilot at Labcorp Drug Development is serving as an "Innovation Incubator" to launch new ways of working across its clinical and laboratory service teams to solve important issues that can impact the client and patients during a clinical trial.

April 14, 2023

Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models

AACR 2023 -- Upwards of 50% of cancer patients will receive radiation during the course of their treatment, mostly through a fractionated dosing schedule. Labcorp Drug Development has a wealth of data across syngeneic models employing a single dose of focal radiation.

April 14, 2023

Transcriptional analysis of TME in MC38 colon carcinoma model following checkpoint inhibition

AACR 2023 -- Colorectal cancer (CRC) is one of the most common cancers with 200,000 U.S. cases per year. Adenocarcinoma is the most common type of CRC, making up 95 percent of all CRC cases. Checkpoint inhibitors used for CRC have shown efficacy for a specific subset of patients.

<span>Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model</span>

April 14, 2023

Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model

AACR 2023 -- Establishing long-term CAR T persistence and efficacy remains a barrier to broader application of CAR T therapies in the clinic, thus development of robust platforms that can provide longitudinal assessments of CAR T persistence and functionality is paramount.

April 14, 2023

Differential immunomodulation following checkpoint blockade in the orthotopic ID8-luc ovarian model

AACR 2023 -- The availability of syngeneic models for ovarian cancer is extremely limited. The ID8-luc ovarian model is established intraperitoneally with disease progression resulting in the accumulation of ascites fluid. However, solid tumors do not reliably form, making assessment of immunomodulation challenging.

管理您的健康

疾病与治疗领域

治疗模式与方法

科学实验室学科

实验室

行业

Now Offering Droplet Digital PCR (ddPCR) and NanoString nCounter

Second generation mRNA vaccines: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant

Environmental Risk Assessment for Pharmaceutical Drugs: Understanding the Evaluation and Implications of Findings to the Regulatory Review of Human Medicines in the Environment

20 critical questions: Helping you optimize reference standards for your biopharmaceutical across its development life cycle

mRNA-lipid nanoparticles: Quality control releasing testing and characterization

United partnerships deliver for the client in a complex NASH study

Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models

Transcriptional analysis of TME in MC38 colon carcinoma model following checkpoint inhibition

Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model

Differential immunomodulation following checkpoint blockade in the orthotopic ID8-luc ovarian model